Asset Details
Do you wish to reserve the book?
43 Clinical logic and reasoning algorithm (CLARA): an AI-enabled whatsapp chatbot for guiding antiarrhythmic drug therapy in atrial fibrillation
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
43 Clinical logic and reasoning algorithm (CLARA): an AI-enabled whatsapp chatbot for guiding antiarrhythmic drug therapy in atrial fibrillation
Do you wish to request the book?
43 Clinical logic and reasoning algorithm (CLARA): an AI-enabled whatsapp chatbot for guiding antiarrhythmic drug therapy in atrial fibrillation
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
43 Clinical logic and reasoning algorithm (CLARA): an AI-enabled whatsapp chatbot for guiding antiarrhythmic drug therapy in atrial fibrillation
2025
Overview
IntroductionAppropriate selection of antiarrhythmic drugs (AADs) in atrial fibrillation (AF) requires consideration of structural heart disease, renal and hepatic function, arrhythmia burden, and drug contraindications. CLARA is an artificial intelligence-powered decision support system that uses a WhatsApp chatbot interface integrated with an Excel-based clinical rules engine to guide AAD selection based on individualised patient profiles.MethodsA synthetic dataset of 150,000 patients with atrial fibrillation was created with varied clinical variables including left ventricular ejection fraction (LVEF), left atrial (LA) size, renal and liver function, AF type, prior AAD exposure, and comorbidities. CLARA was programmed to deliver AAD recommendations. To assess performance, CLARA was tested against cardiologist consensus recommendations in a cohort of 100 complex AF cases, including patients with left ventricular dysfunction, significant structural heart disease, and multiple prior AAD failures (figure 1).ResultsCLARA achieved 91% concordance with expert cardiologist recommendations in selecting the appropriate class and dose of AAD. In 29 patients with LVEF <40%, CLARA correctly excluded Class IC drugs in all cases and recommended amiodarone or rate control. In 18 patients with significant left atrial enlargement, rhythm control was appropriately deprioritised. For patients with prior AAD intolerance (n=26), CLARA accurately identified contraindicated agents. Median response time was under 2 minutes per case.Conclusions/ImplicationsCLARA demonstrates high clinical accuracy and responsiveness in recommending antiarrhythmic therapy in complex AF patients. Its integration of expert-derived algorithms with real-time chatbot interaction offers scalable, structured support for personalising rhythm control strategies. Future work will validate its use in prospective real-world AF populations and explore its integration with electronic health records.Abstract 43 Figure 1[Image Omitted. See PDF.]
Publisher
BMJ Publishing Group LTD
